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management of migraine in adults and children
Michel Lanteri-Minet1,2*, Dominique Valade3, Gilles Geraud4, Christian Lucas5 and Anne Donnet2,6Background
Sponsor
These revised guidelines were prepared at the request of
the Société Française d'Etude des Migraines et des
Céphalées (SFEMC; French Society for the Study of
Migraine Headache). They are a revision of the professional
guidance on the “Diagnosis and therapeutic management of
migraine in adults and children: clinical and economic
aspects” published by the ANAES in 2002 and revised
in 2012. Scope of the guidlines.
These guidelines concern the overall management of
migraine, diagnostic and therapeutic strategies, economic
aspects of the disease and its treatments, menstrual (cata-
menial) migraine, migraine in pregnancy, migraine and
oral contraception, migraine and the menopause.
Headaches other than migraine will not be discussed
except in the context of differential diagnosis. Other
subjects not discussed in these guidelines include dis-
eases associated with migraine apart from psychiatric
problems, risk factors, migraine and smoking, chronic
migraine rare forms and complications of migraine.Patients concerned by the guidelines
These guidelines concern adults and children.Professionals concerned by the guidelines
These guidelines are aimed at all professionals involved in
the management of patients with migraine, including gen-
eral practitioners (GPs), specialists and retail pharmacists.* Correspondence: lanteri-minet.m@chu-nice.fr
1Departement d'Evaluation et de Traitement de la Douleur, Hopital Cimiez, 4,
avenue Reine-Victoria, 06000 Nice, France
2INSERM/UdA, U1107, Neuro-Dol, 8, place Henri-Dunant, BP38, 63001
Clermont-Ferrand, France
This article is a peer-reviewed and revised translation from French (with
permission of Elsevier Masson). For citations please use also the following
reference of the original recommendations: Lantéri-Minet M, Valade D, Géraud
G, Lucas C, Donnet A. Prise en charge diagnostique et thérapeutique de la
migraine chez l'adulte et chez l'enfant. Rev Neurol (Paris) 2013;169:14-29.
Full list of author information is available at the end of the article.
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reproduction in any medium, provided the origGrade of recommendations and study methodology
The recommendations proposed have been classed as
grade A, B or C as follows:
(i) a grade A recommendation is based on scientific
proof established by studies with a high level of
evidence such as adequately-powered comparative,
randomised trials without major bias, or compara-
tive, randomised meta-analyses or decision analyses
based on well-conducted studies.
(ii) a grade B recommendation is based on a scientific
presumption provided by studies with an
intermediate level of proof, such as randomised,
comparative trials with low power, cohort studies,
well-conducted non-randomised comparative
studies or cohort studies.
(iii)a grade C recommendation is based on studies with
a lower level of proof such as case–control studies
or case series.
In the absence of proof, the recommendations pro-
posed are based on professional agreement between
members of the working group. The absence of a level
of proof does not signify that the recommendations are
not pertinent and useful. The absence of proof should
prompt complementary studies wherever possible.
Revision of these recommendations was carried out by
the SFEMC, while respecting AGREE methodology. The
working group was divided into four sub-committees,
each attributed a particular set of themes, a coordinator
and a number of participants:
(i) diagnosis and complementary examinations:
coordinator: Gilles Géraud (neurologist);
participants: Pierric Giraud (neurologist),
Evelyne Guegan-Massardier (neurologist)
(ii) handicap-epidemiology-socioeconomic cost:
coordinator: Dominique Valade (neurologist);
participants: Geneviève Demarquay (neurologist),
André Pradalier (internal medicine)his is an open access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Table 1 Diagnostic criteria for migraine without aura
(ICHD-3 beta)
A. At least five attacks fulfilling to criteria B to D.
B. Headache attacks lasting 4–72 hours (untreated or
unsuccessfully treated).
C. Headaches has at least two of the following 4 characteristics:
1- unilateral location
2- pulsating quality
3- moderate or severe pain intensity
4- aggravation by or causing avoidance of routine physical
activity (e.g. walking or climbing stairs).
D. During headache at least one of the following:
1- nausea and/or vomiting
2- photophobia and phonophobia.
E. Not better accounted for by an order ICHD-3 diagnosis
Table 2 Diagnostic criteria for migraine with aura
(ICHD-3 beta)
A. At least two attacks responding to criteria B and C.
B. B. One or more of the following fully reversible aura symptoms:
1- visual
2- sensory
3- speech and/or language
4- motor
5- brainstem
6- retinal
C. At least two of the following four characteristics:
1- at least one aura symptom spreads gradually over≥ 5 minutes,
and/or 2 or more symptoms occur in succession
2- each individual aura symptom last 5–60 minutes
3- at least one aura symptom is unilateral
4- the aura is accompanied, or followed within 60 minutes by headache
D. Not better accounted for by an order ICHD-3 diagnosis, and transient
ischemic attack has been excluded
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Lucas (neurologist); participants: Gilles Baudesson
(GP), Anne Ducros (neurologist), Serge Iglesias
(neurologist), Claire Lejeune (internal medicine)
(iv) prophylactic treatment: coordinator: Michel
Lantéri-Minet (neurologist); participants:
Henry Becker (neurologist), Anne Donnet
(neurologist), Malou Navez (anaesthetist),
Françoise Radat (psychiatrist).
(v) Jean-Christophe Cuvellier (neuropaediatrician) was
involved in all areas of migraine in children.
A reading group was set up comprised of members of
the SFEMC and independent health professionals (not-
ably community GPs and pharmacists), and members of
the patients’ association. Initially, the project was set up
at the request of the Haute Autorité de la Santé (HAS),
but the latter challenged the majority of members of the
working group on the grounds of potential conflicts of
interest. The SFEMC therefore decided to produce these
recommendations in its own name.
Migraine in adults
Prevalence
In adults between 18- and 65-years, the prevalence of
migraine is estimated to be between 17 and 21% depend-
ing on the diagnostic criteria used: strict migraine 8 − 11%,
probable migraine 9 − 10%, with a female predominance
of 3:1.
Clinical diagnosis
It is recommended that the diagnostic criteria, established
in 1988, revised in 2004 and confirmed in 2013 by the
International Headache Society (IHS) on the basis of ex-
pert consensus, are used. Only the diagnosis of migraine
without aura, typical migraine with aura and probable mi-
graine without aura (satisfying all of the diagnostic criteria
except one) are discussed in this document.
The diagnosis of migraine is based on the following
clinical triad (professional agreement):
(i) recurrent headache disorder manifesting in attacks
(ii) typical characteristics;
(iii)a normal clinical examination.
The IHS diagnostic criteria for migraine without and
with aura are shown below in Tables 1 and 2. These cri-
teria, which are easy to use, enable essential questions to
be asked in a logical order and structure. It is recom-
mended that they are used in a systematic way in daily
practice (professional agreement).
A critical analysis of these criteria shows acceptable
inter-observer variability, good specificity, but poor sen-
sitivity. These criteria are therefore restrictive and donot allow the diagnosis of all cases of migraine. In prac-
tice, to get around this inconvenience and not deprive
some patients with migraine without aura of specific
treatment, it is recommended to use the term « probable
migraine without aura» for cases that fulfil all of the
diagnostic criteria except one. If the five criteria, A, B,
C, D and E are present, the diagnosis is migraine with-
out aura in the strict sense of the term. If one of the cri-
teria, A, B, C or D, is not satisfied completely, the
diagnosis is probable migraine without aura.
There are three typical symptoms: visual, which are
the most frequent (> 90%); sensitive; and aphasic..
A headache occurring after aura may sometimes be
of non-migrainous semiology, or even absent (aura
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the headache. Migraine should be distinguished from a
tension headache: more diffuse headache; non pulsatile;
not aggravated by effort; less intense; without digestive
signs; sometimes accompanied by phonophobia or
photophobia but not both at the same time.1 A loss of
central vision or blurred central vision are possible. Mi-
graine and tension headache may be associated or both
occur in the same patient.
Faced with a migraine attack, two misdiagnoses are
often allocated:
 « sinusitis » when the pain is frontal or sited around
the cheekbone;
 « Arnold’s neuralgia » when the pain starts in the
occipital region and spreads forward as migraine.
Role of complementary examinations
Cerebral TDM and MRI
It is recommended that all patients – migrainous or
not – presenting with a headache of sudden onset,
developing in less than 1 min (thunderclap headache),
are sent to an emergency department for appropriate
complementary examinations.
A CT scan or cerebral MRI is not indicated (profes-
sional agreement):
 In a patient with a migraine defined according to
IHS criteria for migraine, with or without aura;
 To differentiate a migraine from other primary
headaches, in particular a tension headache.
A CT scan or cerebral MRI is recommended (profes-
sional agreement):
 In a patient with migraine attacks appearing after
the age of 50 years;
 In a patient with atypical aura: sudden onset; lasting
for more than 1 h; always occurring on the same
side; and/or without visual symptoms;
 An abnormal clinical examination.
In a known migrainous patient, it is recommended
that a cerebral scan is performed without injection of a
contrast agent in the case of an unusual headache, and if
the scan is normal, a cerebral MRI with arterial and ven-
ous angioMRI can be performed subsequently, within a
period to be determined depending on the context (pro-
fessional agreement).
EEG
There is no indication to perform an EEG in a patient with
migraine defined according to IHS criteria (professional
agreement). EEG is not recommended to eliminate asecondary headache, but cerebral imaging is indicated
(professional agreement).Radiography of sinuses, radiog-
raphy of the neck, ophthalmological examination, orthop-
tic examination, abdominal echography.
There is no indication to perform radiography of the
sinuses, radiography of the neck, an ophthalmological
examination, an orthoptic examination, or abdominal
echography in the investigation of migraine (professional
agreement).
How do we evaluate the handicap caused by
migraine for optimal management?
Migraine is a disabling disease, due to the frequency of
attacks (two or more per month in 42 − 50% of patients),
their duration (>24 h in 39% of patients), their intensity
(severe or very severe in 48 − 74% of patients), the ac-
companying digestive signs and the alterations in profes-
sional, social and familial quality of life.
In order to optimise the management of patients
with migraine, it is recommended (professional agree-
ment) that the patient keep a diary of attacks outlining
the number of days per month with a migraine head-
ache, the duration and intensity of pain, any triggering
factors and all medicines used at each migraine attack
(on prescription or not). The diary should also include
any headaches that occur in between and their treat-
ments. This tool helps the physician to evaluate the se-
verity of the migraine better, to take into account
changes in quality of life, to determine treatment
choice and the modalities of follow-up and to detect
medication abuse.
The functional repercussions of migraine and changes
in productivity can be evaluated using generic and spe-
cific scales, which have been validated in French. Among
these, the HIT-6 and possibly the MIDAS scale are rec-
ommended (professional agreement).
It is recommended that the patient be asked about
the presence of mood or anxiety syndromes, because
these increase disability and may require specific man-
agement. In practice, the HAD scale is proposed to
evaluate the emotional component of migraine (profes-
sional agreement).
Pharmaceutical treatments
Migraine is an under-diagnosed disease: in French studies,
40% of migrainous patients have never consulted a doctor
about their migraine and 60% ignore their migrainous
status and the available treatment options. This state
leads to a high level of self-medication.
A study of the therapeutic behaviour of migrainous
patients shows an overuse of non-specific analgesics,
with several drugs often taken for the same attack
and the absence of significant relief two hours after
the dose in one case in two. Moreover, it reveals an
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immediately, may be justified in patients having se-
vere attacks or attacks that are not relieved by non-
specific treatments.Acute treatment of migraine
Efficacy of different drugs used for acute treatment
Two types of treatment can be distinguished:
 Non-specific treatments (analgesics and non-
steroidal anti-inflammatory drugs (NSAIDs);
 Specific treatments (triptans and ergot derivatives),
which, by acting on 5 HT1B/D receptors, inhibit
neurogenic inflammation and vasodilation supposed
to be the origin of migraine headaches.Non-specific treatments for migraine attacks
Proof of efficacy has been demonstrated for the following
non-specific treatments:
 The following NSAIDs: naproxen, ibuprofen,
ketoprofen and diclofenac (grade A methodology).
Ketoprofen has marketing approval (MA) for the «
treatment of migraine with or without aura » and
ibuprofen has MA for the « treatment of mild to
moderate migraine with or without aura »; the other
NSAIDs do not have specific MA for the acute
treatment of migraine;
 Acetylsalicylic acid (ASS; aspirin) as monotherapy
(grade A methodology), or in association with
metoclopramide (grade A methodology). Only the
association ASS-metoclopramide has MA for the «
symptomatic treatment of migraine and associated
digestive problems »;
 Paracetamol as monotherapy (grade C
methodology). Paracetamol does not have specific
MA for the acute treatment of migraine.
The association of metoclopramide with ASS improves
digestive symptoms, but does not increase the analgesic
effect of ASS (professional agreement). There is no
clinical proof that the association of caffeine with para-
cetamol and aspirin increases their efficacy and this com-
bination cannot be recommended, particularly because
caffeine may induce drug abuse (grade B methodology),
or even addictive behaviour (professional agreement).
It is recommended that opioids are avoided (codeine,
opium, tramadol, morphine and other strong opioids),
alone or in association, as they may induce drug
abuse (grade A methodology), or even addictive behav-
iour (grade B methodology), and can also increase nausea
(grade A methodology).Specific treatments for migraine attacks
Proof of efficacy has been shown for the following spe-
cific treatments:
Triptans (grade A methodology) Triptans are effective
against headaches, but also against the associated digest-
ive symptoms as well as phonophobia and photophobia
(grade A methodology). The following seven triptans
have MA for « treatment of the headache phase of mi-
graine »: almotriptan, eletriptan, frovatriptan, naratrip-
tan, rizatriptan, sumatriptan and zolmitriptan.
There are minimal differences in efficacy and tolerance
between the triptans (grade A methodology), but in
practice there is great interindividual variability (profes-
sional agreement). A patient who is a non-responder to
a triptan during the first attack may then be a re-
sponder (grade A methodology). Before concluding that
a triptan is ineffective, it is recommended that it is
tested over at least three attacks, except if there is poor
tolerance (grade A methodology). A patient who is a
non-responder to one triptan may respond to another
(grade B methodology).
The association sumatriptan and naproxen sodium is
more effective than either of the two drugs taken indi-
vidually (grade A methodology). Taking a triptan early
when the headache is mild is more effective than taking
the triptan when the headache is moderate to severe in
intensity (grade A methodology).
Ergotamine tartrate (grade B methodology) Ergota-
mine tartrate associated with caffeine has MA for the «
acute treatment of migraine ».
Dihydroergotamine (pernasal and injectable) (grade
B methodology) Dihydroergotamine via the pernasal
route has MA for the « acute treatment of migraine ».
The acute treatments for migraine attacks with MA
are shown in Table 3.
Therapeutic strategy for migraine attacks
The following strategy is recommended (professional
agreement). During the first consultation, the patient
should be asked about his/her usual treatment and the
relief provided by this treatment. All acute treatments
for attacks taken alone or in association should be evalu-
ated by the response to the following four questions:
When you take your usual treatment:
 Do you have sufficient relief 1 to 2 h after taking
this treatment?
 Do you use a single dose of this treatment in the
day?
 Is this treatment effective over at least two attacks
out of three?
Table 3 Medicines with marketing approval (MA) for the acute treatment of migraine attacks
Active
component
Dose (per day) Side-effects Contraindications
Symptomatic treatment for migraine attacks and for associated digestive problems
Lysine
acetylsalicylate +
metoclopramide
900 mg at the start of the attack Linked to metoclopramide Linked to metoclopramide
Pheochromocytoma, gastrointestinal
haemorrhage, stenosis or perforation of
the gut, previous history of late drug
dyskinesia, contra-indicated in children
Neuropsychiatric problems, late
dyskinesia, extrapyramidal syndrome,
endocrine problems
Linked to salicylate Linked to salicylate
Digestive problems, haemorrhagic
syndrome, sensitivity reaction, Reyes
syndrome
Gastro-duodenal ulcer, hypersensitivity to
salicylates, haemorrhagic risk
Specific treatments : ergot derivatives
Ergotamine tartrate Adult/child >10 years Ergotism, nausea, vomiting Hypersensitivity to ergot derivatives,
obstructive coronary artery disease, heart
failure, shock, arterial hypertension, severe
infection, severe liver failure
Adult: 2 mg/day (up to 6 mg/day
maximum and 10 mg/week maximum).
Child >10 years: 1/2 dose
Dihydroergotamine Adult >16 years and <65 years Ergotism, precordialgia with the
injectable form, transient local reactions
such as nasal obstruction and
rhinorrhoea with the endonasal form
Endonasal solution
One spray in each nostril at the start of
the attack
Injectable solution
1 renewable ampoule, 30 to 60 min later
2 mg maximum per day and 8 mg
maximum per week
Specific treatments: selective 5HT1 receptor agonists (adults from 18 to 65 years)
Almotriptan Tablet of 12.5 mg/maximum 25 mg/day Vasomotor hot flushes, dizziness, feeling
of weakness, asthenia, somnolence,
nausea, vomiting, rare cases of heart
flutter.
Hypersensitivity, previous history of:
myocardial infarction, ischemic heart
disease, coronary vasospasm (Prinzmetal
angina), peripheral vascular disease,
cerebrovascular accident or transitory
ischemic accident
Eletriptan Tablet of 40 mg/maximum 80 mg/day
Frovatriptan Tablet of 2.5 mg/maximum 5 mg/day
Naratriptan Tablet of 2.5 mg/maximum 5 mg/day
Rizatriptan Tablets of 5 and 10 mg, dry powder of
10 mg/maximum 20 mg/day
Patients with severe liver failure
Sumatriptan Tablet of 50 mg/maximum 300 mg/day
SC injection ampoule 6 mg/maximum
12 mg/day. Nasal spray of 10 and 20
mg/maximum 40 mg/day
Moderate or severe hypertension, of
pins and needles, sensation of heat, of
pressure or of suffocation
Moderate or severe hypertension and in
patients with uncontrolled mild
hypertension
Zolmitriptan Tablet of 2.5 mg, orodispersible at 2.
mg/maximum 10 mg/day
Association with monoamine oxidase
inhibitors (MAOI)
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If the patient answers yes to the four questions, it is
recommended that acute treatment is not modified.If
the patient answers no to at least one of the four ques-
tions, it is recommended that a NSAID and a triptan are
prescribed on the same prescription.
The patient will first take the NSAID and will keep the
triptan as rescue therapy if the migraine is not relieved 1
to 2 h after taking the NSAID. This therapeutic se-
quence should be assessed after three attacks. If the
NSAID is effective over at least two out of three attacks
and if it is well-tolerated, this therapeutic sequenceshould be repeated. If the NSAID is ineffective over at
least two out of three attacks, the triptan should be
taken as first-line to treat following attacks and the treat-
ment should be reevaluated after three new attacks.
If the triptan used straightaway is ineffective over at
least two out of three attacks and is well-tolerated, it is im-
portant to first check that the dose of triptan has been
taken early (in the hour following the onset of the attack)
and if this is not the case, recommend to the patient to re-
try the triptan by taking it early over three consecutive at-
tacks. If the early dose is ineffective or if it is poorly
tolerated, the triptan should be changed and reevaluated
by taking it early over three consecutive attacks. Finally, if
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use a NSAID and a triptan taken simultaneously.
Treatment should be adapted to the severity of the di-
gestive signs. Antiemetics are recommended in patients
with disabling nausea or vomiting.
For all patients, it is recommended to record the number
of days per month when the patient is taking acute treat-
ment, in order to spot overuse, which is frequent in mi-
graine sufferers and may lead to chronic daily headaches. It
is recommended that a patient consults as soon as they use
a treatment regularly two days of more per week for more
than 3 months in view of the possible prescription of
prophylactic treatment (professional agreement).
No treatment has proof of efficacy to reduce the dur-
ation of aura and the triptans are not effective to prevent
headaches when taken at the time of aura (grade B meth-
odology). In the case of a migraine with aura, it is recom-
mended that a NSAID is taken immediately at the start of
aura to prevent or limit the subsequent headache (profes-
sional agreement) and to wait until the start of the head-
ache before taking a triptan (professional agreement).
Prophylactic treatment
Efficacy of different drugs used as prophylactic treatment
Most drugs proposed as prophylactic treatment for mi-
graine are old molecules which have not been evaluated
in controlled therapeutic studies with adequate meth-
odological quality. Taking into account the often weak
methodology, the different drugs have been classed in
three categories: efficacy demonstrated, probable or
doubtful (Table 4):
 Efficacy demonstrated (grade A methodology):
valproate and sodium divalproate, metoprolol (MA),
propranolol (MA), topiramate (MA);
 Efficacy probable (grade B or C methodology):
amitriptyline, atenolol, candesartan, flunarizine
(MA), methysergide (MA/recently reevaluated by
the Commission de Transparence with an
unfavourable benefit/risk ratio), nadolol, naproxen
sodium, nebivolol, oxetorone (MA), pizotifen (MA),
timolol, venlafaxine;
 Efficacy doubtful (grade B or C methodology):
dihydroergotamine (MA), indoramin (MA),
gabapentin
The age of these drugs explains the absence
of correlation between level of proof and MA. Thus,
the following have MA as prophylactic treatment
for migraine: dihydroergotamine, flunarizine, indora-
min, metoprolol, methysergide, oxetorone, pizotifen,
propranolol, topiramate. In addition to the level
of proof and MA, the strategy in terms of prophy-
laxis is also determined by the benefit/risk ratio(professional agreement). No drug has been shown to
have superior efficacy compared to the others (grade
B methodology).
Therapeutic strategy for prophylactic treatment
(professional agreement)
This strategy depends on a number of questions which
the prescriber faces.
When should prophylactic treatment be started? It is
recommended that prophylactic treatment is started:
 As a function of the frequency and intensity of
attacks, but also the familial, social and professional
handicap caused by the attacks;
 As soon as the patient uses treatment(s) for attacks
more than 2 days each week, for 3 months, even in
the case of efficacy, in order to avoid drug abuse.
The initiation of prophylactic treatment should be
associated with an educational strategy in which it
should be explained to the patient that prophylactic
treatment will not prevent attacks but will reduce their
frequency and intensity. Keeping a diary of attacks will
allow a better appreciation of the efficacy of prophy-
lactic treatment.
Which drugs should be used as prophylactic treat-
ment? Considering the level of proof of efficacy,
the benefit/risk ratio and the existence of MA,
the preferred drugs to be used as prophylaxis are pro-
pranolol and metoprolol, in the absence of a contra-
indication to the use of betablockers. In the case of a
contraindication, intolerance or inefficacy of these
betablockers, the choice of drug depends on the con-
text, including comorbidities and migraine severity,
whilst also considering the benefit/risk ratio (weight
gain, sedation, asthenia and teratogenic risk) and the
existence of MA.
How should prophylactic treatment be started? It is
recommended that prophylactic treatment is started as
monotherapy and at a low dose, and that the dose is in-
creased progressively to achieve the optimal dose, taking
into account possible side-effects.
How should prophylactic treatment be evaluated?
Prophylactic treatment is considered to be effective
when it reduces the frequency of attacks by at least 50%.
It is important to also take into account the decrease in
consumption of acute treatments, and the intensity and
duration of attacks. Effectiveness should be evaluated
Table 4 Dosage, side-effects and contraindications for prophylactic treatment
Active component Dosage (per day) Side-effects Contraindications
Propranolol 40-240 mg Frequent: asthenia, poor tolerance to effort Asthma, heart failure, atrio-ventricular block, bradycardia
Metoprolol 100-200 mg
Timolol (without MA) 10-20 mg
Atenolol (without MA) 100 mg Rare: insomnia, nightmares, impotence, depression NB: possibility of aggravation of migraines with aura
Nadolol (without MA) 80-240 mg
Nebivolol (without MA) 5 mg
Oxetorone 60-180 mg (1–3 tablets) as one dose in
the evening
Frequent: somnolence
Rare: diarrhoea necessitating discontinuation of treatment
Amitriptyline 10-50 mg in the evening Dry mouth, somnolence Glaucoma, prostatic adenoma
Weight gain
Pizotifen 3 tablets per day at progressive doses Sedation Glaucoma, uredo-prostatic problems
Weight gain
Rare: digestive problems, dizziness, muscular pain, asthenia
Topiramate 50-100 mg Paresthesia Hypersensitivity to topiramate
Weight loss Pregnancy
Cognitive effects (word-finding difficulties)
Rare: renal calculi, acute myopia associated with secondary angle
closure glaucoma
Sodium valproate (without MA) 500-1000 mg Nausea, weight gain, somnolence, trembling, alopecia, liver attack Liver diseases
Pregnancy
Methysergide 2-6 mg (1–3 tablets) Necessary to stop
treatment for 1 month every 6 months
Frequent: nausea, dizziness, insomnia Hypertension, heart failure, arteriopathologies, gastric
ulcer, liver and kidney failure, association with triptans
Rare: retroperitoneal fibrosis
Flunarizine 10 mg (1 tablet in the evening). Not for
more than 6 consecutive months
Frequent: somnolence, weight gain Depressive syndrome, extra-pyramidal syndrome
Rare: depression, extrapyramidal syndrome
Gabapentin (without MA) 1200-2400 mg Nausea, vomiting, convulsions, somnolence, ataxia, dizziness Hypersensitivity to gabapentin
Dihydroergotamine 10 mg Nausea Association with triptans
Indoramin 50 mg Somnolence, nasal congestion, dry mouth, ejaculation problems Hypersensitivity to one of the components of the
drug product, Parkinson’s disease, severe heart, liver
and kidney failure
Candesartan (without MA) 8-16 mg Arterial hypotension, dizziness Hypersensitivity, severe liver and kidney failure
2nd and 3rd trimester of pregnancy
Venlafaxin (without MA) 75-150 mg Nausea, dizziness, hypersudation, somnolence, nervousness,
dry mouth
Hypersensitivity to venlafaxine, association with
non-selective MAOI, congenital galactosaemia,
breast feeding
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possibilities:
 The dose can be increased, in the absence of side-
effects;
 Another treatment may be proposed.
The association of two prophylactic treatments at a
lower dose may be envisaged with the aim of reducing
the side-effects of each drug, after having tested them
separately. In the case of repeated failures, compliance
or drug abuse should be investigated.When should prophylactic treatment be stopped? In
the case of success, prophylactic treatment at the effect-
ive dose should be continued for six months to one year,
adapted as closely as possible to the spontaneous evolu-
tion of migraine and then decreased very slowly before
being stopped. The same treatment may be restarted if
the frequency of attacks increases again.Other treatments
Relaxation, retrocontrol (biofeedback) and cognitive and
behavioural therapies for the management of stress have
proof of efficacy (grade A methodology) and may be rec-
ommended. Data in the literature are inconclusive about
the efficacy of acupuncture (grade A methodology), but
do not recommend homeopathy (grade A methodology)
or spinal manipulation (professional agreement) for the
prevention of migraine.Characteristics of migraine in children
Prevalence
The prevalence is estimated to be between 3 and 10%.Positive diagnosis
Migraine in children can be distinguished from adult
migraine by:
 Shorter attacks (1–48 h in children <15-years ac-
cording to the IHS);
 A more frequent bilateral localisation;
 Digestive problems are often more important;
 Frequent initial pallor.
As in adults, it is recommended to use the diagnosis
of «probable migraine without aura» when all diagnostic
criteria are fulfilled except one, so as not to deprive
some children of specific management. In this context,
the IHS criteria for the diagnosis of migraine without
aura have a lower sensitivity in children than in adults.Place of complementary examinations
The place of complementary examinations is the same
in children as in adults. However, the indications for
neuroimaging should be extended due to the difficulties
in the aetiological diagnosis of headaches in children.
Evaluation of handicap
No quality of life scale has been validated in French for
migraine in children. It is recommended to keep a diary
of attacks in order to help the child and his/her family
identify triggering factors, to evaluate the efficacy of
treatments and to allow the doctor to appreciate the se-
verity of the migraine (frequency, intensity of attacks, as-
sociated digestive signs) and its repercussions on daily
life (absenteeism from school).
Acute treatment of migraine attacks
The following drugs are recommended in children and
adolescents as first-line:
 Ibuprofen in children >6 months (grade A
methodology);
 Then (professional agreement): diclofenac in
children >16 kg, naproxen in children >6 years
or >25 kg, aspirin as monotherapy, paracetamol as
monotherapy.
In the treatment of moderate to severe migraine at-
tacks, sumatriptan nasal spray (10–20 mg) is effective
(grade A methodology) and has specific MA in adoles-
cents from 12 to 17 years. It is recommended (profes-
sional agreement):
 To take treatment as early as possible;
 To use the rectal route in the case of nausea and
vomiting;
 To use the nasal route from 12-years of age or in
children >35 kg;
 To use sumatriptan nasal spray in the case of failure
with paracetamol, aspirin and NSAIDs;
 For the triptans and ergot derivatives, to wait for the
onset of the headache to treat an attack with aura.
Prophylactic treatment
Non-pharmaceutical treatments
Relaxation, retrocontrol (biofeedback) and cognitive and
behavioural therapies for the management of stress can
be recommended (grade B methodology). These treat-
ments are more effective than betablockers (grade B
methodology).
Pharmaceutical treatments
It is recommended that prophylactic drug treatment is
used after failure of non-pharmacological treatments
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ments has MA in this paediatric indication. In the absence
of established scientific proof, the following drugs may
be proposed, in no preferential order (professional
agreement):
 Amitriptyline, 3–10 mg/day;
 Flunarizine in children >10 years, 5 mg/day;
 Metoprolol, 25–50 mg/day;
 Oxetorone, 15–30 mg/day;
 Pizotifen in children >12 years, 1 mg/day;
 Propranolol, 2–4 mg/kg/day;
 Topiramate, 50–100 mg/day.
It is recommended to use these drugs at low doses,
in order to limit the side-effects, particularly their
sedative effects.
Migraine and the hormonal cycle in women
Migraine and pregnancy
Management of migraine in a woman desiring a pregnancy
Confronted with a female migraine sufferer who
wishes to become pregnant, the following recommen-
dations can be made regarding the planning of mi-
graine treatment:
 Reassure her that, as far as it is known, migraine is
not associated with a poor evolution of pregnancy
(grade A methodology);
 Reassure her by indicating that for the great
majority of women with migraine, pregnancy is
associated with a partial or even complete remission
of migraine attacks (grade A methodology);
 Do not start prophylactic treatment (professional
agreement);
 According to recommendations suggest acute
treatment favouring paracetamol, but not limiting
the use of aspirin, NSAIDs and triptans (ideally
favouring triptans in the first 2 weeks of the cycle
and aspirin or NSAIDs during the rest of the cycle)
(professional agreement);
 Inform her about the antimigraine drugs that are
contraindicated during pregnancy (ergot derivatives,
valproate and sodium divalproate; aspirin and
NSAIDs from the end of the fifth month of
pregnancy) (professional agreement);
 Remind her of the risk of some drugs (notably
ibuprofen) and phytotherapeutics available in the
pharmacy or parapharmacy without prescription
(professional agreement);
 Inform her that migraine can be treated during her
pregnancy, if necessary, and that breast feeding
(which is advised) will be possible (professional
agreement).Steps to take in a female migraine sufferer who has used
antimigraine drugs unaware that she was pregnant
A woman with migraine may seek advice because she
has just become pregnant and has used antimigraine
drugs when she did not know that she was pregnant.
Taking antimigraine drugs prophylactically when she
did not know that she was pregnant For most of the
prophylactic antimigraine drugs, it is sufficient to re-
assure the patient and inform them that no surveillance
of the pregnancy is necessary (except if the patient has
taken prophylaxis with ergot derivatives [DHE or methy-
sergide] or valproate or sodium divalproate) (profes-
sional agreement). In the case of prophylactic treatment
with a drug belonging to the class of betablockers (pro-
pranolol and metoprolol) or with tricyclic antidepres-
sants (amitriptyline), this drug should be stopped
immediately bearing in mind that if it is justified by the
migraine, this treatment could be continued at the min-
imal effective dose (professional agreement).
In the case of prophylactic treatment with a drug that is
neither a betablocker nor a tricyclic, the drug should be
stopped. If prophylactic treatment is justified however, the
drug should be replaced by a betablocker (propranolol or
metoprolol) or possibly by a tricyclic (amitriptyline) (pro-
fessional agreement).
Taking acute antimigraine treatment when the patient
does not know that she is pregnant For most antimi-
graine drugs used as acute treatment for attacks, it is ad-
visable to reassure the patient and inform them that no
surveillance of the pregnancy is necessary (except if the
patient has used large quantities of DHE or ergotamine
tartrate) (professional agreement).
Concerning the continuation of a drug during preg-
nancy, the advice will depend on the drug concerned
(professional agreement):
 Paracetamol: its use as first-line is possible;
 Aspirin and NSAIDs: paracetamol is preferred as
first-line, but these drugs can be used as rescue ther-
apy during the second and third trimesters, while
they are contraindicated from the end of the fifth
month;
 DHE and ergotamine tartrate: their use is positively
contraindicated;
 Triptans: although pharmacovigilance data are
reassuring, their use is contraindicated.
In all cases, exposure of the patient to drugs should be
declared to pharmacovigilance (pharmacovigilance unit
of the hospital, pharmacovigilance department of the
company producing the drug concerned, reference
centre for teratogenic agents [http://www.lecrat.org]).
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pregnancy when treatment is necessary
A number of recommendations allow treatment in a
pregnant migraine sufferer to be optimised if necessary.
These recommendations are as follows:
 Plan monthly follow-up visits when remission from
attacks is not observed (professional agreement);
 Propose acute treatment with paracetamol as first-
line and a NSAID as rescue therapy (only during the
first and second trimesters because after this time
aspirin and NSAIDs are contraindicated) (profes-
sional agreement);
 If prophylactic treatment is necessary, favour a
betablocker (propranolol or metoprolol) or as
second-line a tricyclic antidepressant (amitriptyline)
(reminding the patient that it is necessary to stop
these drugs before delivery) (professional
agreement);
 Remind the patient about the risks of these drugs
(ibuprofen in particular) and of the phytotherapeutic
preparations available from the pharmacy or
parapharmacy without a prescription (professional
agreement).
In all cases where a drug is prescribed, it is necessary
to remember that exposure of the patient to the drug
should be declared to pharmacovigilance (pharmacovigi-
lance unit of the hospital, pharmacovigilance department
of the company producing the drug concerned, reference
centre for teratogenic agents: http://www.lecrat.org).
Catamenial (menstrual) migraine
According to the international classification of head-
aches by the IHS (ICHD-III beta), the diagnosis of men-
strual migraine depends on the appearance, during at
least two out of three consecutive menstrual cycles, of
an attack without aura starting between the second day
before and the third day following the menstrual period,
whether this menstrual period corresponds to natural
menstruation or withdrawal bleeding following the dis-
continuation of oral oestroprogestative contraception.
The diagnosis of catamenial migraine (or purely men-
strual migraine) is made in migraine sufferers who do
not cite any other attack outside the menstrual period.
Although nearly half of migraine sufferers report men-
strual attacks, less than 10% report a catamenial mi-
graine (grade B methodology).
Monthly attacks are secondary to the fall in oestrogens
occurring during the luteal phase of the natural menstrual
cycle or during the discontinuation of oral oestroprogesta-
tive contraception (grade B methodology). Catamenial mi-
graine indicates a particular sensitivity to these hormonal
variations in women who suffer from them.Compared to attacks occurring outside the menstrual
period, menstrual attacks are characterised by a greater se-
verity, a longer duration and a poorer response to acute
treatment (grade A methodology). These attacks may have
serious repercussions as some patients may suffer anxious
anticipation, the time in the menstrual cycle drives them
to «anticipate» the appearance of monthly menstrual at-
tack (professional agreement).
Menstrual migraine attacks should be treated in the
same way as migraine attacks occurring outside the men-
strual period (professional agreement).
In patients suffering from catamenial migraine and if
acute treatment is not effective, sequential prophylactic
treatment may be considered, that is to say, limited to
the menstrual period. Several options can be considered
knowing that none have specific MA in this indication.
It is possible to use cutaneous oestradiol at a dose of
1.5 mg/day for 7 days starting on the second day before
the menstrual period or withdrawal bleeding (grade B
methodology). More recently, some triptans have been
shown to be effective as prophylactic sequential therapy:
frovatriptan at a daily dose of 2.5 mg two times/day
(grade A methodology), naratriptan at a dose of 1 mg
two times/day (grade B methodology) and zolmitriptan
at a dose of 2.5 mg two times/day (grade B methodology).
In patients taking oral contraception, menstrual migraine
can be prevented by using a continuous oestroprogestative
or a pure progestative (professional agreement).
Migraine and oral contraception
The use of oral contraception in a migraine sufferer should
be considered carefully bearing two questions in mind:
 Is there a risk that the contraception will aggravate
the migraine?
 Will the contraception expose the patient to a
particular vascular risk?
The association between the prevalence of migraine
and past or present use of oral contraception is linked to
the presence of ethinyl-oestradiol (independent of the
dose) but not to that of the progestative (grade A meth-
odology). In spite of this association, the influence of
contraception on migraine is subject to great inter-
individual variability; thus, oral contraception is not in
principal contraindicated in women with migraine (pro-
fessional agreement).
Young patients (<35 years) suffering from migraine
with aura have an increased neurovascular risk (grade A
methodology). This neurovascular risk is increased in
the presence of cofactors, particularly smoking and the
use of oestroprogestative oral contraception (grade A
methodology). In young migraine sufferers with aura,
particularly when they smoke, oestroprogestative oral
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which is purely progestative or another means of contra-
ception should be preferred (professional agreement).
Migraine and hormonal treatment of the menopause (HRT)
The use of hormone replacement therapy (HRT) in a
woman with migraine should be considered bearing two
questions in mind:
 Is there a risk that HRT will have an influence on
the migraine?
 Is there a risk of cerebral ischaemia from HRT in
the migrainous patient?
Influence of HRT on the course of migraine
Transversal studies (grade B methodology) have demon-
strated a significant association between HRT use and
persistence of migraine attacks. Longitudinal studies
(grade B methodology) have shown that transdermal
oestradiol induces fewer migraines than oral conjugated
oestrogens and that HRT taken continuously induces
fewer migraine attacks than discontinuous treatment.
HRT, migraine and the risk of cerebral infarction
HRT is an independent risk factor for cerebral infarction
with a low but significant relative risk (RR = 1.29; 95%CI:
1.06 − 1.56) as shown in a meta-analysis (grade A meth-
odology). No data are available on the risk associatied
with both migraine and HRT combined.
Overall, migraine is not a contraindication for HRT, but
if aggravation of migraine is observed, notably with aura
on HRT, alternatives should be discussed with the patient,
including a change to a transdermal form, a reduction of
the oestradiol dose, or stopping HRT completely.
Future developments
Taking into account the current clinical developments
(such as CGRP receptor antagonists and other non-
vasoconstrictive treatments), the recommendations of
the working group should be amended when necessary
during the next five years. Future actions should also be
adapted to the recommendations for patients.
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